Please login to the form below

Not currently logged in
Email:
Password:

Ophthotech

This page shows the latest Ophthotech news and features for those working in and with pharma, biotech and healthcare.

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme

The results of two phase III trials of pegpleranib - an anti-PDGF aptamer originally developed by OphthoTech - showed that adding it to therapy with Lucentis (ranibizumab) in patients with the neovascular ... While a minor blow to Novartis as well as

Latest news

  • Novartis licenses Ophthotech eye drug in $1bn deal Novartis licenses Ophthotech eye drug in $1bn deal

    s Avastin (bevacizumab), so the Ophthotech deal gives Novartis an alternative therapeutic option as well as the possibility of developing a combination treatment. ... Ophthotech has retained rights to the drug in the US and will also earn royalties on

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 400. Ophthotech / Novartis. Commercialisation. 1. and co-development licence. Fovista (start p3) for treatment of wet age-related macular degeneration.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics